From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in ... Benzinga Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from a randomized study comparing REVLIMID® (lenalidomide) plus rituximab to lenalidomide monotherapy in previously treated patients with recurrent ... |
